Naloxone Education and Access Act

To amend the Public Health Service Act with respect to opioid overdose reversal medication access, education, and co-prescribing grant programs, and for other purposes. 1. Short title This Act may be cited as the Naloxone Education and Access Act 2. Opioid overdose reversal medication access, education, and co-prescribing grant programs Section 545 of the Public Health Service Act ( 42 U.S.C. 290ee (1) in the section heading, by striking access and education access, education, and co-prescribing (2) in subsection (a)— (A) in the subsection heading, by striking to States (B) in the matter preceding paragraph (1), by striking States eligible entities (C) in paragraph (1), by striking for pharmacists to dispense a drug or device approved or cleared that increase access to drugs and devices approved, cleared, or otherwise legally marketed (D) by redesignating paragraphs (3) and (4) as paragraphs (5) and (6), respectively; (E) by inserting after paragraph (2) the following: (3) encourage health care providers to co-prescribe, as appropriate, drugs or devices approved, cleared, or otherwise legally marketed under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose; (4) support innovative community-based distribution programs of drugs or devices approved, cleared, or otherwise legally marketed under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose; ; (F) in paragraphs (5) and (6), as so redesignated, by striking approved or cleared approved, cleared, or otherwise legally marketed (3) in subsection (b)— (A) by striking State eligible entity (B) by striking approved or cleared approved, cleared, or otherwise legally marketed (4) in subsection (c)— (A) in the matter preceding paragraph (1), by striking States eligible entities (B) by striking approved or cleared approved, cleared, or otherwise legally marketed (5) in subsection (d)— (A) in paragraph (1), by striking A State An eligible entity (B) in paragraph (2), by striking 3 5 (C) by amending paragraph (3) to read as follows: (3) Limitation An eligible entity may use— (A) not more than 10 percent of a grant under this section for educating the public pursuant to subsection (a)(6); and (B) not less than 20 percent of a grant under this section to offset cost-sharing for distribution and dispensing of drugs or devices approved, cleared, or otherwise legally marketed under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose. ; (6) in subsection (e), by striking a State an eligible entity (7) in subsection (f)— (A) by striking A State An eligible entity (B) by striking in the State in the jurisdiction of the eligible entity (C) by striking approved or cleared approved, cleared, or otherwise legally marketed (8) by amending subsection (g) to read as follows: (g) Definitions In this section: (1) Eligible entity The term eligible entity (2) Indian Tribe The term Indian Tribe (3) Standing order The term standing order (4) Tribal organization The term Tribal organization (5) Urban Indian organization The term Urban Indian organization ; and (9) in subsection (h)(1)— (A) by striking $5,000,000 $10,000,000 (B) by striking 2017 through 2019 2023 through 2027

Summary: Naloxone Education and Access Act This bill reauthorizes through FY2027, expands eligibility for, and otherwise makes changes to a grant program that supports access to medications that reverse opioid overdoses (e.g., naloxone).